BIOHARVEST SCIENCES IS A GLOBAL LEADER IN BOTANICAL SYNTHESIS AND PLANT CELL BIOLOGY

– Innovative and disruptive Botanical Synthesis Platform opening the gate for patentable Botanical Drugs

• New Contract Development and Manufacturing business unit launched February 26, 2024 with two industry contracts. Pharma, Cosmeceutical, Nutraceutical and Nutrition customers can now develop patentable and consistent plant-based molecules using our process.

– Our patented Botanical Synthesis technology has been validated by the successful commercialization of VINIA, the first product developed on our platform.

• Full Year 2023 Revenue Increased 2.3x to $12.7 Million USD
• Q1 2024 Revenue beat guidance at $5.34 million and Q2 2024 Revenue Guidance is $5.7-$6.0 million
• First quarter 2024 gross margins improved to 56%, as compared to 37% in the first quarter of 2023

– New “VINIA Inside” delivery systems are in the product pipeline, including additional Hot Beverage products, hydration powders, and new Beauty/Anti Aging products

– Major innovation pipeline planned in the polyphenol/antioxidant vertical with additional products being developed from Olive and Pomegranate cell banks

– Strong IP platform with multiple patents obtained and pending

– High Scalability with low cap ex requirements ($3-4M)

– Significant leadership capability and Board/Advisory Board expertise

– Current market capitalization offers significant upside